Regeneron convinces PTAB to review Novartis syringe patent

The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

PTAB year in review: A shifting landscape and outlook for 2026

2 January 2026 With the unprecedented changes at the PTAB in 2025, what could the year ahead hold for the agency? Lawyers from Sterne Kessler explore.

Europe

UPC: A review of 2025 and what to expect in 2026

31 December 2025 As the Unified Patent Court continues in its third year, there are inevitable issues that continue to arise as it grows as a jurisdiction, writes Darren Smyth of EIP.

Europe

Mental health in IP: ‘We have a clear picture of the problem’

30 December 2025 The Life in the Law 2025 report sheds light on the mental health challenges faced by legal professionals, revealing the links between wellbeing, inclusion and modern working practices. IP Inclusive’s Andrea Brewster explores how the findings offer clear guidance for meaningful change.

More features

PTAB year in review: A shifting landscape and outlook for 2026

UPC: A review of 2025 and what to expect in 2026

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Regeneron convinces PTAB to review Novartis syringe patent

More on this story

Editor's picks

Editor's picks

More features